PER-123-09
Completed
未知
A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer´s Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- -G30
- Sponsor
- ASTRAZENECA PERU S.A.,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provision of informed consent before the start of any procedure related to the study. Patients deemed unable to provide informed consent may be enrolled if the informed consent of the Legally Acceptable Representative has been obtained in accordance with local regulations.
- •Clinical diagnosis of probable AD according to the NINCDS\-ADRDA criteria.
- •History of progressive impairment of memory and other cognitive functions for at least 12 months
- •Hachinski Ischemia Score \<4
- •Computed Tomography (CT) or Magnetic Resonance Exam (MRI) within the last 6 months (performed after the onset of dementia) consistent with the diagnosis of AD. If the CT / MRJ test is older than 6 months, the patient will need to renew the CT / MRI to confirm the diagnosis.
- •MMSE score from 16 to 24\.
- •Men and women, 55\-85 years, including the day of enrollment
- •The patient must live with an appropriate caregiver at home, or in a community accommodation. The caregiver should be able to accompany the patient to the visits to the center or attend the study visits in the patient´s case. The same caregiver is needed for visits where ADCS\-CGIC is evaluated.
- •The patient and the caregiver understand and are capable and wish to meet all the requirements of the study, judging by the investigator.
- •The patient and the caregiver should understand, speak and read the local language.
Exclusion Criteria
- •Possible, probable or definitive vascular dementia in accordance with the criteria of the National Institute of Neurological Disorders and Stroke Association\-Association Internationale pour la Recherche et l´Enseignement en Neurosciences (NINDS\-AIREN)
- •Significant neurological disease or dementia other than AD, for example, mixed dementia, frontotemporal dementia and Parkinson´s disease, which may affect cognition or the ability to complete the study.
- •Current major depressive disorder or other major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Edition (DSM\-IV).
- •Clinically significant or unstable current respiratory disease, gastrointestinal disease, heart disease, cerebrovascular disease, hematological disease, liver disease, kidney disease, urogenital disease, or other major disease, as judged by the researcher.
- •Current systemic disease that, at the discretion of the researcher, probably impairs or affects the safety of the participant, influences cognitive evaluations or affects the ability to complete the study.
- •History of seizures or loss of consciousness within 6 months before enrollment.
- •History of any malignant disease within the last 5 years, with the exception of minor superficial cutaneous disease (ie, basal cell carcinoma and squamous cell carcinoma).
- •Myocardial infarction or acute coronary syndrome within the last year.
- •Clinically significant ECG abnormalities according to the investigator´s criteria based on the evaluation by a centrally located experienced cardiologist who interprets the ECG.
- •Prolonged QTcF\> 450 msec or shortened QTcF \<350 msec or family history of long QT syndrome.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD - PACEChronic Obstructive Pulmonary DiseaseEUCTR2005-004110-32-DEAstraZeneca AB190
Active, not recruiting
Phase 1
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial)Cardiovascular diseasesMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2017-003510-16-FRSanofi-aventis Recherche & Développement6,667
Active, not recruiting
Phase 1
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-002954-35-SKsanofi-aventis recherche & développement5,000
Active, not recruiting
Phase 1
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-001804-43-HUSanofi-aventis Recherche & Développement800
Active, not recruiting
Not Applicable
A study on the safety and effectivenes of study drug in reducing the number of seizures in subjects with epilepsy. The drug will be studied in young people aged from 12 to less than 18 years. It will assess if the drug has any effect on the ability to know, learn, perceive, recognize, remember, think and understand. Also, if it has effects on growth and development.Inadequately controlled partial onset seizuresTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2010-018518-56-HUEisai Limited132